Le Corvec Maëna, Jezequel Caroline, Monbet Valérie, Fatih Nadia, Charpentier Frédéric, Tariel Hugues, Boussard-Plédel Catherine, Bureau Bruno, Loréal Olivier, Sire Olivier, Bardou-Jacquet Edouard
University Bretagne Sud, IRDL, FRE CNRS 3744, Vannes, France.
DIAFIR, Rennes, France.
PLoS One. 2017 Oct 11;12(10):e0185997. doi: 10.1371/journal.pone.0185997. eCollection 2017.
BACKGROUND & AIMS: Prognostic tests are critical in the management of patients with cirrhosis and ascites. Biological tests or scores perform poorly in that situation. Mid-infrared fibre evanescent wave spectroscopy (MIR-FEWS) which allows for global serum metabolic profiling may provide more relevant information by measuring a wider range of metabolic parameters in serum. Here we present the accuracy of a MIR-FEWS based predictive model for the prognosis of 6 months survival in patients with ascites and cirrhosis.
Patients with ascites were prospectively included and followed up for 6 months. MIR-FEWS spectra were measured in serum samples. The most informative spectral variables obtained by MIR-FEWS were selected by FADA algorithm and then used to build the MIR model. Accuracy of this model was assessed by ROC curves and 90%/10% Monte Carlo cross-validation. MIR model accuracy for 6 months survival was compared to that of the Child-Pugh and MELD scores.
119 patients were included. The mean age was 57.36±13.70, the MELD score was 16.32±6.26, and the Child-Pugh score was 9.5±1.83. During follow-up, 23 patients died (20%). The MIR model had an AUROC for 6 months mortality of 0.90 (CI95: 0.88-0.91), the MELD 0.77 (CI95: 0.66-0.89) and Child-Pugh 0.76 (CI95: 0.66-0.88). MELD and Child-Pugh AUROCs were significantly lower than that of the MIR model (p = 0.02 and p = 0.02 respectively). Multivariate logistic regression analysis showed that MELD (p<0.05, OR:0.86;CI95:0.76-0.97), Beta blockers (p = 0.036;OR:0.20;CI95:0.04-0.90), and the MIR model (p<0.001; OR:0.50; CI95:0.37-0.66), were significantly associated with 6 months mortality.
In this pilot study MIR-FEWS more accurately assess the 6-month prognosis of patients with ascites and cirrhosis than the MELD or Child-Pugh scores. These promising results, if confirmed by a larger study, suggest that mid infrared spectroscopy could be helpful in the management of these patients.
预后测试在肝硬化腹水患者的管理中至关重要。在这种情况下,生物学测试或评分表现不佳。中红外光纤倏逝波光谱技术(MIR - FEWS)可实现血清整体代谢谱分析,通过测量血清中更广泛的代谢参数可能提供更相关的信息。在此,我们展示基于MIR - FEWS的预测模型对腹水和肝硬化患者6个月生存率预后的准确性。
前瞻性纳入腹水患者并随访6个月。在血清样本中测量MIR - FEWS光谱。通过FADA算法选择MIR - FEWS获得的最具信息性的光谱变量,然后用于构建MIR模型。通过ROC曲线和90%/10%蒙特卡洛交叉验证评估该模型的准确性。将MIR模型对6个月生存率的准确性与Child - Pugh评分和MELD评分进行比较。
纳入119例患者。平均年龄为57.36±13.70,MELD评分为16.32±6.26,Child - Pugh评分为9.5±1.8。随访期间,23例患者死亡(20%)。MIR模型对6个月死亡率的AUROC为0.90(95%CI:0.88 - 0.91),MELD为0.77(95%CI:0.66 - 0.89),Child - Pugh为0.76(95%CI:0.66 - 0.88)。MELD和Child - Pugh的AUROC显著低于MIR模型(分别为p = 0.02和p = 0.02)。多因素逻辑回归分析显示,MELD(p<0.05,OR:0.86;95%CI:0.76 - 0.97)、β受体阻滞剂(p = 0.036;OR:0.20;95%CI:0.04 - 0.90)和MIR模型(p<0.001;OR:0.50;95%CI:0.37 - 0.66)与6个月死亡率显著相关。
在这项初步研究中,MIR - FEWS比MELD或Child - Pugh评分更准确地评估腹水和肝硬化患者的6个月预后。如果能被更大规模的研究所证实,这些有前景的结果表明中红外光谱技术可能有助于这些患者的管理。